Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant

Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.

Although the failure of Amgen Inc.'s Kyprolis to show superior progression-free survival in a Phase III head-to-head trial against classmate Velcade surprised many analysts, they consistently noted that the regimens used in the comparative trial are almost entirely abandoned in the multiple myeloma setting.

The company is trying to further ameliorate the trial failure by enlisting oncologists to state that the data would not...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category